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Abstract Peroxynitrite (ONOO
3
) is a `reactive nitrogen
species' that can be formed (among other reactions) by
combination of superoxide (O
2
W3
) and nitric oxide (NO
W
)
radicals. It is being increasingly proposed as a contributor to
tissue injury in several human diseases. The evidence presented
for peroxynitrite participation usually includes the demonstration
of increased nitrotyrosine levels in the injured tissue. Indeed, this
is often the only evidence presented: the assumption is that
formation of nitrotyrosine is a biomarker specifically diagnostic
of ONOO
3
production. The present article examines this
assumption and concludes that nitrotyrosine is a biomarker for
`nitrating species' rather than being specific for ONOO
3
.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
The free radical nitric oxide (nitrogen monoxide, NO
W
) is
produced in vivo by constitutive and inducible nitric oxide
synthase enzymes [1,2] and probably also by non-enzymic re-
actions [3,4] such as the reaction of nitrites with acid in the
stomach [5]. Nitric oxide plays important physiological and
pathological roles [1^7]. One of the mechanisms by which
excess NO
W
can injure tissues is by its rapid [8] reaction with
superoxide radical (O
2
W3
) to give peroxynitrite, ONOO
3
.
O
W3
2
NO
W
!ONOO
3
1
Peroxynitrite undergoes reaction with CO
2
, protonation, iso-
merization and decomposition at physiological pH to give
noxious products that deplete antioxidants and oxidize and
nitrate lipids, proteins and DNA [6,9^19]. The detailed mech-
anisms by which ONOO
3
and species derived from it cause
modi¢cation of biomolecules are still incompletely understood
[6,9^21] but there is little doubt about the cytotoxicity asso-
ciated with ONOO
3
formation at physiological pH
[6,9,10,22^25].
Peroxynitrite has been suggested to be involved in the pa-
thology of a wide range of diseases (Table 1). In all the cases
listed in Table 1, part (or often all) of the evidence that im-
plicates ONOO
3
is the detection of 3-nitrotyrosine (Fig. 1) in
the injured tissues. Nitrotyrosine is generated when ONOO
ÿ
is added to tyrosine itself, or to proteins containing tyrosine
residues, under physiological conditions and the rate of nitra-
tion is usually elevated if transition metal ions or certain met-
alloproteins (e.g. CuZnSOD) are present [9,10,46^49]. The
chemical identity of the nitrating species is uncertain [9^
11,17,46^48,50]. Detection of 3-nitrotyrosine is most often
achieved by antibody immunostaining of tissues [26,49], but
HPLC-based [30,49,51,52,86] and GC/MS-based [27,53] tech-
niques have also been described.
2. Is nitrotyrosine speci¢c as a marker of peroxynitrite
generation?
Peroxynitrous acid is known to be capable of leading to
nitration of tyrosine. However, is the presence of nitrotyrosine
a speci¢c biomarker of ONOO
3
generation? The obvious
question is whether other species can nitrate tyrosine. Let us
examine some of the candidates.
2.1. Nitric oxide
There is no evidence that NO
W
reacts with free tyrosine or
tyrosyl residues within proteins. Such a reaction is unlikely
given the generally poor reactivity of NO
W
with non-radicals.
However, NO
W
reacts extremely fast with tyrosyl (tyr-O
W
) rad-
icals, the second-order rate constant being greater than 10
9
M
31
s
31
[54]. It is possible that the addition products C-nitro-
so and/or O-nitrosotyrosine are reversibly formed (Fig. 1).
Nitrosotyrosine could conceivably be converted to 3-nitrotyr-
osine by ROS generated at sites of in£ammation [54]. Quench-
ing of the active site tyrosyl radical of ribonucleotide reduc-
tase probably accounts for the inhibition of this enzyme by
NO
W
[55]. Tyrosyl radicals have been detected in a variety of
other enzymes including cyclooxygenase, photosystem II of
chloroplasts and in haem proteins after reaction with H
2
O
2
[56^59]. Hence it is possible (but remains to be proved) that
free radical attack upon tyrosine to generate Tyr^O
W
followed
by addition of NO
W
and rearrangement could generate nitro-
tyrosine. Many free radicals can oxidize Tyr to Tyr-O
W
.
2.2. Nitrogen dioxide
The brown choking acidic free radical gas nitrogen dioxide
(NO
2
W
) is a well-known toxin, formed by combustion of or-
ganic materials. It is an important constituent of polluted in-
door and outdoor air [60] and cigarette smoke [61]. Exposure
of tyrosine to NO
2
W
in aqueous solution generates both nitro-
tyrosine and bityrosine [47,62,63] and NO
2
W
can also nitrate
tyrosine residues in proteins [47,62,63]. Even cigarette smoke
nitrates tyrosine [61]. Indeed, NO
2
W
production may be one
mechanism accounting for tyrosine nitration on addition of
ONOO
3
at physiological pH; production of bityrosine in the
reaction mixtures is consistent with Tyr-O
W
formation [47].
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Exposing animals to large amounts of NO
2
W
gas could
therefore lead to protein nitration. However, it seems that
high levels of NO
2
W
are needed to achieve tyrosine nitration,
even in vitro [63]. Many of the human subjects and other
animals used as healthy controls in the studies summarized
in Table 1 lived in large industrial cities and would thus be
breathing outdoor and indoor air containing some NO
2
W
[60].
Presumably, some subjects were smokers. Yet tissues from
healthy subjects rarely show much (if any) immunostaining
for nitrotyrosine and levels of nitrotyrosine detected by GC/
MS or HPLC are usually low, quoted as [30,64] less than 100
nM (or as 91 nitrated tyrosine per 10
6
residues [86]) in human
body £uids. Hence normal atmospheric levels of NO
2
W
(a few
ppm at most) seem unlikely to confound nitrotyrosine meas-
urements.
Nevertheless, the fast reaction of NO
2
W
with tyrosine radi-
cals generates nitrotyrosine (see below). NO
2
W
can arise from
NO
W
oxidation (although this is a slow reaction), by oxidation
of NO
2
3
(Section 2.5) and perhaps from ONOO
3
at physio-
logical pH.
2.3. Nitrous acid
Breakdown of NO
W
in aqueous solution generates NO
2
3
as
the major end-product [65] whereas decomposition of
ONOO
ÿ
(via ONOOH) produces largely NO
3
3
[9]. NO
2
3
levels in healthy subjects have been reported as 0.5^13 WM
in plasma, 15 WM in respiratory tract lining £uids, 30^210
WM in saliva,V1 WM in CSF and 0.4^60 WM in gastric juice.
Elevated levels have been reported in many human diseases
[66^72], e.g. greater than 30 WM in serum of AIDS patients
with pulmonary involvement [73]. Most NO
2
3
generated from
NO
W
in vivo or absorbed from the gut is oxidized to NO
3
3
,
although NO
3
3
can be re-reduced to give NO
2
3
in the gut
and in the oral cavity [74,75]. Exposure of NO
2
3
to low pH
generates oxides of nitrogen via formation and decomposition
of nitrous acid, HNO
2
. This could happen at the low pH of
the human stomach [5] and might possibly occur in ischaemic
tissues [4], and in the phagolysosome, but in most other tis-
sues the pH probably never falls to a su¤ciently low value to
permit HNO
2
generation. It thus seems that HNO
2
formation
would be an unlikely source of nitrating species in most tis-
sues, but could contribute to events in the stomach (Table 1).
Nevertheless, it must not be forgotten that the `standard' lab-
oratory preparation of peroxynitrite [9] involves initial reac-
tion of HNO
2
with H
2
O
2
HONOHOOH!HOONOH
2
O
2.4. Nitryl (nitronium) chloride
Eiserich et al. [76], extending earlier work of Kono [77],
showed that reaction of NO
2
3
with hypochlorous acid
(HOCl), generates a product that can nitrate tyrosine and
other aromatic compounds. Detailed chemical characteriza-
tion [76] strongly suggests that this compound is nitryl (nitro-
nium) chloride, NO
2
Cl. Hypochlorous acid is well known to
be produced at sites of in£ammation by activated neutrophils
[78], where NO
2
3
can be present in WM amounts (see above).
Addition of HOCl [79,80] or of NO
2
Cl [76] can lead to chlori-
nation of tyrosine, generating 3-chlorotyrosine (Fig. 2).
Although there is as yet no direct evidence for NO
2
Cl pro-
duction in vivo (HOCl generated in vivo can react with many
molecular targets other than NO
2
3
or tyrosine), the data in
[76] suggest that caution should be exercised in attributing
nitration to the e¡ects of ONOO
3
. Of course, ONOO
3
can-
not chlorinate aromatic rings, so observation of nitration in
the absence of chlorination would suggest that NO
2
Cl is not
involved.
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Fig. 2. Conversion of tyrosine to 3-nitrotyrosine and 3-chlorotyro-
sine.
Fig. 1. Structures of C-nitroso (A) and O-nitroso (B) tyrosines.
Table 1
Some of the conditions in which the formation of peroxynitrite has
been implicated as causing tissue injury
Condition Reference
Atherosclerosis [26,27] (but see [28])
Sporadic inclusion-body myositis [29]
Rheumatoid arthritis [30]
In£ammatory bowel disease [31^33]
Neurodegenerative disease [24,25,34,35]
Acute in£ammation [36]
Carbon monoxide toxicity [37]
Adult respiratory distress syndrome [38,39]
Skin in£ammation [40]
Gastritis (H. pylori infection) [41]
Cystic ¢brosis [42]
Endotoxic shock [43,44]
Ageing of skeletal muscle [45]
Viral infection [83]
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2.5. Myeloperoxidase
Hypochlorous acid is generated by the H
2
O
2
-dependent ox-
idation of Cl
3
by the haem-containing enzyme myeloperoxi-
dase [78]
Cl
3
 H
2
Oÿ!
MPO
HOClHCl
Myeloperoxidase is a `non-speci¢c' peroxidase, capable of us-
ing H
2
O
2
to oxidize a wide range of substrates. Van der Vliet
et al. [81] showed that MPO (as well as lactoperoxidase and
horseradish peroxidase) can oxidize NO
2
3
in the presence of
H
2
O
2
into a species able to nitrate tyrosine. Given that per-
oxidases can catalyze single-electron oxidations, and that the
product of one-electron oxidation of NO
2
3
is NO
2
W
, it is pos-
sible that the nitrating species is NO
2
W
HRPH
2
O
2
!compound I
compound INO
3
2
!compound IINO
W
2
compound IINO
3
2
!HRPNO
W
2
However, two-electron oxidation of NO
2
3
to NO
2

is also
conceivable. Formation of the nitrating species from NO
2
3
still occurred in the presence of physiological (100 mM) levels
of Cl
3
[81]. Myeloperoxidase/H
2
O
2
is capable of oxidizing
tyrosine to tyrosyl radicals [84,85]. Such radicals could com-
bine with NO
2
W
to form nitrotyrosine, or with each other,
generating dityrosine [81]. Indeed, any oxidizing species capa-
ble of oxidizing both tyrosine to tyrosyl radicals and NO
2
3
to
NO
2
W
should lead to nitrotyrosine formation (Section 2.2):
ONOO
3
-derived species might generate nitrotyrosine in this
way [47].
Again, there is no direct evidence that nitration of tyrosine
residues by peroxidase/H
2
O
2
/NO
2
3
systems happens in vivo.
However, it is hard to rule out: nitration by this mechanism
would not lead to simultaneous chlorination unless, of course,
HOCl was being generated, in which case both HOCl itself
and NO
2
Cl could contribute to aromatic chlorination. Studies
on myeloperoxidase-de¢cient patients or transgenic animal
MPO `knockouts' might provide useful insights.
3. Conclusion
On present evidence, it cannot be stated de¢nitively that the
formation of nitrotyrosine in vivo is due to ONOO
3
. Condi-
tions favouring formation of excess O
2
W3
and NO
W
are usually
also those in which there is phagocyte recruitment and acti-
vation, and activated neutrophils are well-known to release
MPO (indeed, levels of MPO in a tissue are often used as a
marker of neutrophil in¢ltration [78]). It is probably safest to
say that the detection of nitrotyrosine provides evidence for
generation of reactive nitrogen species rather than speci¢cally
ONOO
3
.
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